Eosinophilic Esophagitis (EoE) Market Outlook

Thelansis’s “Eosinophilic Esophagitis (EoE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eosinophilic Esophagitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Eosinophilic Esophagitis (EoE) Overview

Eosinophilic Esophagitis (EoE), often characterized as the “asthma of the esophagus,” is a chronic, immune-mediated Type 2 inflammatory disease marked by dense eosinophilic infiltration of the esophageal mucosa, driving progressive structural remodeling and functional impairment. Clinical presentation is highly age-dependent: children frequently present with vomiting, abdominal pain, regurgitation, and feeding difficulties, whereas adolescents and adults typically experience dysphagia, recurrent food impactions, and chest discomfort driven by fibrostenotic narrowing. Diagnosis requires an endoscopic biopsy demonstrating ≥15 eosinophils per high-power field (eos/hpf) isolated to the esophagus. The pathophysiology is strongly linked to atopy, with the vast majority of patients possessing a concurrent history of asthma, eczema, or allergic rhinitis. While historically thought to be unresponsive to acid suppression, modern clinical guidelines now recognize high-dose proton pump inhibitors (PPIs) as a highly effective, first-line anti-inflammatory treatment, utilized alongside targeted dietary allergen elimination and swallowed topical corticosteroids. For patients refractory to conventional therapies or those with severe multi-atopic disease, biologic therapies—most notably the IL-4/IL-13 inhibitor dupilumab—have revolutionized the standard of care by addressing the underlying immunological cascade, while endoscopic dilation remains a critical mechanical intervention for managing established fibrotic strictures.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)